Skip to main content
HANDOK Inc. logo

HANDOK Inc. — Investor Relations & Filings

Ticker · 002390 ISIN · KR7002390003 KO Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-09-26 Regulatory Filings
Country KR South Korea
Listing KO 002390

About HANDOK Inc.

https://www.handok.co.kr/en/

Handok Inc. is a total healthcare company that develops, manufactures, and distributes a comprehensive range of healthcare solutions. Its portfolio includes prescription drugs, general medicine, medical devices, and in-vitro diagnostics. The company's core business focuses on therapeutic areas such as diabetes, cardiovascular and musculoskeletal diseases, and psychoneurotic disorders, in addition to human vaccines. Positioning itself as a "Health Innovator," Handok provides products and services aimed at prevention, diagnosis, and health management. The company collaborates with global enterprises and manages the entire value chain from sourcing and development to commercialization.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(담도암 치료제 HDB001A의 식품의약품안전처 제 2상 임상시험계획 승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Handok) regarding a 'voluntary disclosure' (자율공시) of a clinical trial application (IND) for a biliary tract cancer treatment. It details the trial phase, purpose, and regulatory status with the Ministry of Food and Drug Safety. Since it is a specific regulatory announcement regarding corporate operations and clinical trial status that does not fit into financial reporting or shareholder meeting categories, it is classified as a Regulatory Filing (RNS).
2023-09-26 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Handok regarding their 'Fair Trade Compliance Program' (CP) operations for the first half of 2023 and plans for the second half. This type of disclosure, which details internal governance, compliance systems, and ethical management practices, falls under the category of Governance Information (CGR) as it describes the company's internal rules and compliance structure.
2023-08-11 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '한독' (Handok) covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial information, business operations, management discussions, and financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
투자판단관련주요경영사항
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure filed by Handok regarding the voluntary withdrawal of a clinical trial application for a biliary tract cancer treatment (HDB001A) with the Ministry of Food and Drug Safety. It details the reasons for withdrawal, the clinical trial status, and future plans. As this is a specific regulatory announcement regarding material business operations (clinical trial status) that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2023-08-11 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Disclosure' (영업(잠정)실적) for Handok, detailing quarterly financial results (revenue, operating profit, net income) for Q2 2023. It provides key financial highlights rather than a full report. According to the filing definitions, an initial announcement of quarterly financial results is classified as an Earnings Release (ER). Q2 2023
2023-07-27 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. In the context of Korean corporate filings (DART system), this type of disclosure regarding stock option grants is classified as a regulatory filing that does not fit into specific categories like M&A or financial reports, and is best categorized under RNS (Regulatory Filings) as it serves as a formal public disclosure of corporate action.
2023-07-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.